At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGON CG Oncology Inc.
Trading 04-07 13:21:54 EDT
68.86
+1.31
+1.94%
High69.07Low67.01Vol627.96K
Open68.56D1 Closing67.55Amplitude3.05%
Mkt Cap5.81BTradable Cap4.67BTotal Shares84.44M
T/O42.57MT/O Rate0.93%Tradable Shares67.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE -Virgin Galactic, Humana, Broadcom
Reuters  ·  04-07 19:41
BUZZ-U.S. STOCKS ON THE MOVE -Virgin Galactic, Humana, Broadcom
CG Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  04-07 18:41
CG Oncology Is Maintained at Buy by HC Wainwright & Co.
BUZZ-CG Oncology rises after brokerage lifts PT ahead of pivotal bladder cancer data
Reuters  ·  04-07 18:39
BUZZ-CG Oncology rises after brokerage lifts PT ahead of pivotal bladder cancer data
CG Oncology price target raised to $100 from $80 at H.C. Wainwright
TIPRANKS  ·  04-07 17:55
CG Oncology price target raised to $100 from $80 at H.C. Wainwright
CG Oncology, Inc. : H.c. Wainwright Raises Target Price to $100 From $80
THOMSON REUTERS  ·  04-07 17:51
CG Oncology, Inc. : H.c. Wainwright Raises Target Price to $100 From $80
CG Oncology, Inc. (CGON) Gets a Buy from JonesTrading
TIPRANKS  ·  04-07 04:37
CG Oncology, Inc. (CGON) Gets a Buy from JonesTrading
A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering
Simply Wall St.  ·  04-06 06:18
A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering
LifeSci Capital Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-28
LifeSci Capital Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating
MT Newswires Live  ·  03-26
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
TIPRANKS  ·  03-25
Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-19
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON)
CG Oncology Director James Mulay Disposes of USD 125,412 in Common Shares
Reuters  ·  03-18
CG Oncology Director James Mulay Disposes of USD 125,412 in Common Shares
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
Simply Wall St.  ·  03-16
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
CG Oncology price target raised to $72 from $65 at BofA
TIPRANKS  ·  03-14
CG Oncology price target raised to $72 from $65 at BofA
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
TIPRANKS  ·  03-02
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029
Simply Wall St.  ·  03-02
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029
CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
TIPRANKS  ·  02-28
CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
CG Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  02-28
CG Oncology Is Maintained at Buy by HC Wainwright & Co.
Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M
MT Newswires Live  ·  02-27
Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate
Benzinga  ·  02-27
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate

Introduction

Company Name.
CG Oncology Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--